Literature DB >> 21410764

SOX2 and nestin expression in human melanoma: an immunohistochemical and experimental study.

Alvaro C Laga1, Qian Zhan, Carsten Weishaupt, Jie Ma, Markus H Frank, George F Murphy.   

Abstract

SOX2 is an embryonic neural crest stem-cell transcription factor recently shown to be expressed in human melanoma and to correlate with experimental tumor growth. SOX2 binds to an enhancer region of the gene that encodes for nestin, also a neural progenitor cell biomarker. To define further the potential relationship between SOX2 and nestin, we examined co-expression patterns in 135 melanomas and 37 melanocytic nevi. Immunohistochemical staining in 27 melanoma tissue sections showed an association between SOX2 positivity, spindle cell shape and a peripheral nestin distribution pattern. In contrast, SOX2-negative cells were predominantly epithelioid, and exhibited a cytoplasmic pattern for nestin. In tissue microarrays, co-expression correlated with tumor progression, with only 11% of nevi co-expressing SOX2 and nestin in contrast to 65% of metastatic melanomas, and preliminarily, with clinical outcome. Human melanoma lines that differentially expressed constitutive SOX2 revealed a positive correlation between SOX2 and nestin expression. Experimental melanomas grown from these respective cell lines in murine subcutis and dermis of xenografted human skin maintained the association between SOX2-positivity, spindle cell shape, and peripheral nestin distribution. Moreover, the cytoplasmic pattern of nestin distribution was observed in xenografts generated from SOX2-knockdown A2058 melanoma cells, in contrast to the peripheral nestin pattern seen in tumors grown from A2058 control cells transfected with non-target shRNA. In aggregate, these data further support a biologically significant linkage between SOX2 and nestin expression in human melanoma.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21410764      PMCID: PMC3439836          DOI: 10.1111/j.1600-0625.2011.01247.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  38 in total

1.  CNS stem cells express a new class of intermediate filament protein.

Authors:  U Lendahl; L B Zimmerman; R D McKay
Journal:  Cell       Date:  1990-02-23       Impact factor: 41.582

2.  Expression of the stem cell marker nestin in peripheral blood of patients with melanoma.

Authors:  A Fusi; S Ochsenreither; A Busse; A Rietz; U Keilholz
Journal:  Br J Dermatol       Date:  2010-03-24       Impact factor: 9.302

Review 3.  Cellular tensegrity: exploring how mechanical changes in the cytoskeleton regulate cell growth, migration, and tissue pattern during morphogenesis.

Authors:  D E Ingber; L Dike; L Hansen; S Karp; H Liley; A Maniotis; H McNamee; D Mooney; G Plopper; J Sims
Journal:  Int Rev Cytol       Date:  1994

Review 4.  Cutaneous mesenchymal stem cells: status of current knowledge, implications for dermatopathology.

Authors:  Klaus Sellheyer; Dieter Krahl
Journal:  J Cutan Pathol       Date:  2009-12-01       Impact factor: 1.587

5.  Expression of the neuroectodermal intermediate filament nestin in human melanomas.

Authors:  V A Flørenes; R Holm; O Myklebost; U Lendahl; O Fodstad
Journal:  Cancer Res       Date:  1994-01-15       Impact factor: 12.701

6.  Nestin and SOX9 and SOX10 transcription factors are coexpressed in melanoma.

Authors:  Renato M Bakos; Tanja Maier; Robert Besch; Dominik S Mestel; Thomas Ruzicka; Richard A Sturm; Carola Berking
Journal:  Exp Dermatol       Date:  2010-08       Impact factor: 3.960

7.  Growth and invasion of human melanomas in human skin grafted to immunodeficient mice.

Authors:  I Juhasz; S M Albelda; D E Elder; G F Murphy; K Adachi; D Herlyn; I T Valyi-Nagy; M Herlyn
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

8.  Nestin in human skin: exclusive expression in intramesenchymal skin compartments and regulation by leptin.

Authors:  Stephan Tiede; Jennifer E Kloepper; Nancy Ernst; Burkard Poeggeler; Charli Kruse; Ralf Paus
Journal:  J Invest Dermatol       Date:  2009-06-25       Impact factor: 8.551

9.  Vimentin contributes to human mammary epithelial cell migration.

Authors:  C Gilles; M Polette; J M Zahm; J M Tournier; L Volders; J M Foidart; P Birembaut
Journal:  J Cell Sci       Date:  1999-12       Impact factor: 5.285

Review 10.  Cellular tensegrity: defining new rules of biological design that govern the cytoskeleton.

Authors:  D E Ingber
Journal:  J Cell Sci       Date:  1993-03       Impact factor: 5.285

View more
  33 in total

1.  Sex-determining region Y-box 2 expression predicts poor prognosis in human ovarian carcinoma.

Authors:  Jing Zhang; Doo Young Chang; Imelda Mercado-Uribe; Jinsong Liu
Journal:  Hum Pathol       Date:  2012-03-07       Impact factor: 3.466

Review 2.  Stem cells and targeted approaches to melanoma cure.

Authors:  George F Murphy; Brian J Wilson; Sasha D Girouard; Natasha Y Frank; Markus H Frank
Journal:  Mol Aspects Med       Date:  2013-10-19

3.  TET2 Negatively Regulates Nestin Expression in Human Melanoma.

Authors:  Camilla B F Gomes; Karina G Zechin; Shuyun Xu; Rafael F Stelini; Ines N Nishimoto; Qian Zhan; Ting Xu; Gungwei Qin; Nathaniel S Treister; George F Murphy; Christine G Lian
Journal:  Am J Pathol       Date:  2016-04-18       Impact factor: 4.307

Review 4.  Immunoplasticity in cutaneous melanoma: beyond pure morphology.

Authors:  Francesca Maria Bosisio; Joost J van den Oord
Journal:  Virchows Arch       Date:  2017-01-05       Impact factor: 4.064

5.  Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  World J Clin Oncol       Date:  2012-03-10

6.  SOX2 contributes to melanoma cell invasion.

Authors:  Sasha D Girouard; Alvaro C Laga; Martin C Mihm; Richard A Scolyer; John F Thompson; Qian Zhan; Hans R Widlund; Chung-Wei Lee; George F Murphy
Journal:  Lab Invest       Date:  2011-12-19       Impact factor: 5.662

7.  Sox2 is not required for melanomagenesis, melanoma growth and melanoma metastasis in vivo.

Authors:  V Cesarini; E Guida; F Todaro; S Di Agostino; V Tassinari; S Nicolis; R Favaro; S Caporali; P M Lacal; E Botti; A Costanzo; P Rossi; E A Jannini; S Dolci
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

8.  Sox2 is dispensable for primary melanoma and metastasis formation.

Authors:  S M Schaefer; C Segalada; P F Cheng; M Bonalli; V Parfejevs; M P Levesque; R Dummer; S K Nicolis; L Sommer
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

Review 9.  Progression of cutaneous melanoma: implications for treatment.

Authors:  Stanley P L Leong; Martin C Mihm; George F Murphy; Dave S B Hoon; Mohammed Kashani-Sabet; Sanjiv S Agarwala; Jonathan S Zager; Axel Hauschild; Vernon K Sondak; Valerie Guild; John M Kirkwood
Journal:  Clin Exp Metastasis       Date:  2012-08-15       Impact factor: 5.150

10.  Fatty Acid Synthase and Acetyl-CoA Carboxylase Are Expressed in Nodal Metastatic Melanoma But Not in Benign Intracapsular Nodal Nevi.

Authors:  Jad Saab; Maria Laureana Santos-Zabala; Massimo Loda; Edward C Stack; Travis J Hollmann
Journal:  Am J Dermatopathol       Date:  2018-04       Impact factor: 1.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.